Holen Sie sich die Stockscreener-App
1.68
1.20%
0.02
Handel nachbörslich:
1.64
-0.04
-2.38%
Schlusskurs vom Vortag:
$1.66
Offen:
$1.61
24-Stunden-Volumen:
655.35K
Relative Volume:
1.31
Marktkapitalisierung:
$32.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.26M
KGV:
-0.8235
EPS:
-2.04
Netto-Cashflow:
$-24.69M
1W Leistung:
-25.66%
1M Leistung:
-32.26%
6M Leistung:
+35.48%
1J Leistung:
-77.63%
1-Tages-Spanne:
$1.60
$1.72
1-Wochen-Bereich:
$1.57
$2.60
52-Wochen-Spanne:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.68 | 32.35M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
What data driven models say about Annovis Bio Inc.’s futureMarket Volume Report & Weekly High Return Stock Forecasts - newser.com
Is Annovis Bio Inc. stock dividend yield sustainableFed Meeting & Risk Controlled Stock Pick Alerts - newser.com
Tools to monitor Annovis Bio Inc. recovery probabilityQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - newser.com
Can Annovis Bio Inc. stock hit record highs againMarket Growth Report & Entry Point Confirmation Alerts - newser.com
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning - MyChesCo
Heatmap analysis for Annovis Bio Inc. and competitorsTrade Risk Summary & Expert Curated Trade Setup Alerts - newser.com
Why Annovis Bio Inc. stock could be next big winnerAnalyst Downgrade & High Conviction Buy Zone Alerts - newser.com
Annovis Announces $6 Million Registered Direct Offering of Common Stock - MarketScreener
How Annovis Bio Inc. stock trades during market volatility2025 Price Momentum & Smart Investment Allocation Tips - newser.com
Multi asset correlation models including Annovis Bio Inc.Market Rally & High Accuracy Trade Signal Alerts - newser.com
Full technical analysis of Annovis Bio Inc. stockJuly 2025 Opening Moves & Community Consensus Stock Picks - newser.com
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MyChesCo
Visual trend scoring systems applied to Annovis Bio Inc.Market Growth Review & Step-by-Step Trade Execution Guides - newser.com
Annovis Bio raises $6 million in registered direct offering By Investing.com - Investing.com South Africa
Annovis Bio raises $6 million in registered direct offering - Investing.com India
Annovis Bio to Raise $6 Million in Registered Direct Offering; Shares Fall - MarketScreener
Annovis announces $6 million registered direct offering of common stock - MarketScreener
Annovis Announces $6 Million Registered Direct Offering Of Common Stock - TradingView
Annovis Bio, Inc. Announces $6 Million Registered Direct Offering of Common Stock - Quiver Quantitative
Statistical indicators supporting Annovis Bio Inc.’s strengthJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Is Annovis Bio Inc. stock in buy zone after pullback2025 Market Outlook & Smart Money Movement Tracker - newser.com
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap - MSN
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer’s Patients - citybuzz
Will Annovis Bio’s Therapeutic Innovation Drive Stock Growth? - timothysykes.com
Annovis Bio reports buntanetap reduces inflammation in Alzheimer’s patients By Investing.com - Investing.com Australia
Annovis Bio reports buntanetap reduces inflammation in Alzheimer’s patients - Investing.com
Does Annovis Bio Inc. show high probability of reboundQuarterly Risk Review & Technical Entry and Exit Tips - newser.com
Annovis Bio Reports Promising Biomarker Results for Buntanetap in Alzheimer’s Disease Treatment - Quiver Quantitative
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment - The Manila Times
Annovis announces novel biomarker data in Alzheimer's patients supporting buntanetap's potential as a disease-modifying treatment - MarketScreener
Annovis Announces Novel Biomarker Data in Alzheimer’s - GlobeNewswire
Reduced IL-5, IL-6, S100A12, IFN-γ and NFL — Annovis' buntanetap shows biomarker signals in 2/3 AD - Stock Titan
Will Annovis Bio Inc. stock go up soon2025 Fundamental Recap & Daily Volume Surge Trade Alerts - newser.com
Freedom Village at Brandywine Raises Over $6,000 for Alzheimer’s Research - MyChesCo
What analysts say about Annovis Bio Inc stockGap Up/Gap Down Analysis & Ride the Trends That Billionaires Follow - earlytimes.in
How high can Annovis Bio Inc. stock goQuarterly Portfolio Review & Safe Swing Trade Setups - newser.com
Why Annovis Bio Inc. stock stays on buy listsJuly 2025 Action & Weekly Watchlist for Hot Stocks - newser.com
Why analysts raise outlook for Annovis Bio Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
Why Annovis Bio Inc. stock is considered a top pickEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Ipca Laboratories Limited Earnings Review What Investors Need to KnowRetail Investor Activity & Small Investment Wealth Growth - earlytimes.in
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):